Florian Ebner1, Reyn van Ewijk2, Achim Wöckel3, Katharina Hancke4, Lukas Schwentner4, Visnja Fink4, Rolf Kreienberg4, Wolfgang Janni4, Maria Blettner5. 1. Universität Ulm, Klinik für Frauenheilkunde und Geburtshilfe, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: florian.ebner@uniklinik-ulm.de. 2. Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI), Obere Zahlbacher Str. 69, 55131 Mainz, Germany; Universität Mainz, Institut für Wirtschaftswissenschaften, Jakob-Welder-Weg 4, 55128 Mainz, Germany. 3. Universität Würzburg, Frauenklinik und Poliklinik, Josef-Schneider-Str. 4, Haus C15, 97080 Würzburg, Germany. 4. Universität Ulm, Klinik für Frauenheilkunde und Geburtshilfe, Prittwitzstr. 43, 89075 Ulm, Germany. 5. Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI), Obere Zahlbacher Str. 69, 55131 Mainz, Germany.
Abstract
PURPOSE: The tumor biology of older breast cancer patients (oBCP) is usually less aggressive, however applied adjuvant treatment is often less potent resulting in an impaired disease free survival and overall survival in this group. This study tries to answer the following questions for the biological subtypes of oBCP (70+ y): METHODS: Between 1992 and 2008 the BRENDA ('BRENDA' = quality of BREast caNcer care unDer evidence-bAsed guidelines) study group recorded medical data of 17 participating certified breast cancer centers in Germany. We performed a retrospective multi-center database analysis of 5632 patient records. Guideline-adherent-treatment (GL+) of oBCP(n = 1918) was compared to GL+ of yBCP(n = 3714). RESULTS: OBCP were more likely to have hormone receptor positive (HR+) and HER2neu negative (HER2-) breast cancer (77.5% vs 74.5%). The rate of GL- was significantly different (p < 0.001) between the age groups and the biological subgroups (yBCP vs oBCP: 21.8%vs38.8% (HR+/HER2-); 30.6%vs49.7% (HR+/HER2+); 23.6%vs69.5% (HR-/HER2+); 31.4%vs67.8% (TNBC)). The survival parameters for HR+/HER2- and TNBC were significantly worse in case of GL- regarding chemotherapy, and if applicable endocrine therapy. A similar association only existed in HR-/HER2+ tumors for GL- for radiotherapy and in HR+/HER2+ tumors for chemotherapy. CONCLUSIONS: Beside the significantly different distribution of biological subtypes in the age groups there is an association between biological subtype, and GL+ influencing survival parameters in oBCP.
PURPOSE: The tumor biology of older breast cancerpatients (oBCP) is usually less aggressive, however applied adjuvant treatment is often less potent resulting in an impaired disease free survival and overall survival in this group. This study tries to answer the following questions for the biological subtypes of oBCP (70+ y): METHODS: Between 1992 and 2008 the BRENDA ('BRENDA' = quality of BREast caNcer care unDer evidence-bAsed guidelines) study group recorded medical data of 17 participating certified breast cancer centers in Germany. We performed a retrospective multi-center database analysis of 5632 patient records. Guideline-adherent-treatment (GL+) of oBCP(n = 1918) was compared to GL+ of yBCP(n = 3714). RESULTS: OBCP were more likely to have hormone receptor positive (HR+) and HER2neu negative (HER2-) breast cancer (77.5% vs 74.5%). The rate of GL- was significantly different (p < 0.001) between the age groups and the biological subgroups (yBCP vs oBCP: 21.8%vs38.8% (HR+/HER2-); 30.6%vs49.7% (HR+/HER2+); 23.6%vs69.5% (HR-/HER2+); 31.4%vs67.8% (TNBC)). The survival parameters for HR+/HER2- and TNBC were significantly worse in case of GL- regarding chemotherapy, and if applicable endocrine therapy. A similar association only existed in HR-/HER2+ tumors for GL- for radiotherapy and in HR+/HER2+ tumors for chemotherapy. CONCLUSIONS: Beside the significantly different distribution of biological subtypes in the age groups there is an association between biological subtype, and GL+ influencing survival parameters in oBCP.
Authors: Ena Niño de Guzmán; Yang Song; Pablo Alonso-Coello; Carlos Canelo-Aybar; Luciana Neamtiu; Elena Parmelli; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Zuleika Saz Parkinson; Iván Solà; Adrián Vásquez-Mejía; Ignacio Ricci-Cabello Journal: Breast Cancer Res Treat Date: 2020-05-06 Impact factor: 4.872
Authors: Ignacio Ricci-Cabello; Adrián Vásquez-Mejía; Carlos Canelo-Aybar; Ena Niño de Guzman; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Ivan Solà; Yang Song; Luciana Neamtiu; Elena Parmelli; Zuleika Saz-Parkinson; Pablo Alonso-Coello Journal: BMC Health Serv Res Date: 2020-10-07 Impact factor: 2.655